Brand-name GLP-1 medications won't be expensive forever. Patent expirations, biosimilar development, and global competition are on a collision course with current pricing. Here's the timeline that will reshape what you pay.
Disclosure: Some links on this page are affiliate links. Patent information from public filings as of May 2026.
Patent Expiration Timeline
| Drug | Manufacturer | Key Patent Expiry | Generic/Biosimilar ETA |
|---|---|---|---|
| Semaglutide (Ozempic/Wegovy) | Novo Nordisk | ~2031-2032 (US) | 2032-2034 |
| Tirzepatide (Mounjaro/Zepbound) | Eli Lilly | ~2036 (US) | 2037-2039 |
| Liraglutide (Saxenda/Victoza) | Novo Nordisk | Expired (some patents) | Biosimilars in development |
Note: Patent landscapes are complex. Multiple patents cover formulation, delivery devices, manufacturing processes, and uses. The dates above reflect key compound patents — additional patents may extend effective exclusivity.
What Happens After Patent Expiry
GLP-1 medications are peptides, making them "biologics" rather than simple small-molecule drugs. This means generic versions are technically "biosimilars" — and the pathway to approval is more complex:
- Generic small molecules — identical copy, ANDA application, typically 80-90% price drop. Think: generic metformin.
- Biosimilars — highly similar but not identical, more extensive testing required, typically 15-40% price drop initially. Think: biosimilar insulin.
Don't expect 90% price drops on day one. Biosimilar GLP-1s will likely launch at 15-40% below brand price, then gradually decrease as more competitors enter. The dramatic price drops from compounding (80-90% below brand) may still be the cheapest option for years after generics launch.
International Competition: The China Factor
Over 17 Chinese pharmaceutical companies are developing GLP-1 medications. Some key patent expirations in China occur earlier than in the US (around March 2026 for some semaglutide patents). Chinese-manufactured GLP-1s could reach international markets (outside the US) well before American generics are available.
For US patients, this matters because:
- Global competition puts pressure on Novo Nordisk and Eli Lilly to lower prices
- Bulk API sourcing from international manufacturers could further reduce compounded medication costs
- The US generic/biosimilar timeline remains separate from international markets
Next-Generation GLP-1s in Development
Beyond generic versions of existing drugs, entirely new GLP-1 medications are in development from multiple companies. These could offer better efficacy, fewer side effects, or lower prices through competition:
- Survodutide (Boehringer Ingelheim) — dual glucagon/GLP-1 agonist
- Orforglipron (Eli Lilly) — oral, non-peptide GLP-1 (potentially cheaper to manufacture)
- Retatrutide (Eli Lilly) — triple agonist (GIP/GLP-1/glucagon) with ~24% weight loss in trials
- CagriSema (Novo Nordisk) — semaglutide + amylin analogue
Orforglipron is particularly significant for pricing — as a non-peptide, it could be manufactured as a traditional small-molecule generic after patent expiry, enabling the 80-90% price drops we see with conventional generics.
What to Do Now
Generics are 5-10+ years away. In the meantime, compounded alternatives offer the closest thing to generic pricing available today:
- Semaglutide key patents expire ~2031-2032; biosimilars could follow by 2032-2034
- Tirzepatide patents extend to ~2036; generics not expected until late 2030s
- Biosimilar GLP-1s will likely launch at 15-40% below brand — not 90% like traditional generics
- Orforglipron (oral, non-peptide) could enable true generic pricing after its patent expires
- Chinese competition (17+ companies) is putting global pressure on pricing now
- Compounded options ($130-$179/mo) provide near-generic pricing today — no need to wait